Indirect inhibitors of MYCN, such as the BET bromodomain inhibitor, the CDK7 inhibitor, the AURKA inhibitor, the HAUSP inhibitor and the ODC inhibitor have clearly shown benefit in suppressing MYCN-amplified tumor growth in the preclinical studies, and a few of these inhibitors including bromodomain inhibitor GSK525762, AURKA inhibitor MLN8237 and ODC inhibitor DFMO are being evaluated in the clinic for MYCN-driven cancers. This evidence concerns the gene MYCN and neoplasm.